Phase I, Dose Escalation Clinical Trial of GRASPA (Red Blood Cells Encapsulating L-Asparaginase) in Patients With Pancreatic Carcinoma
Inclusion Criteria:
- Exocrine pancreatic adenocarcinoma cytologically or histologically confirmed
- Locally advanced and non-resectable with invasion of the superior mesenteric artery
(stage III) or metastatic (stage IV) as defined by TNM 2002 classification (UICC
2002)
- resistant to a first or second line chemotherapy with gemcitabine
- Patient aged between 18 to 70 years
- Signed Informed Consent Form
- Life expectancy ≥ 12 weeks
- Accurate measurement of tumor volume by imagery (in at least one dimension)
- Presence of one or several tumor markers (CEA and CA 19.9)
- ECOG Prognostic Score : 0, 1 or 2
- Patient beneficiary of a Social Security Insurance
Exclusion Criteria:
- Patient with an endocrine or acinar pancreatic tumor
- Patient with known or suspected cerebro-meningeal metastases
- Haemoglobin level greater than 13 g/L
- Patient hypersensitive to L-asparaginase or have had prior exposure to any form of
L-asparaginase
- Splenic vein thrombosis < 3 months or under active treatment
- Anti-vitamin K treatment
- Hepatic Insufficiency unrelated to pancreatic cancer
- Renal insufficiency unrelated to pancreatic cancer
- Pancreatitis or pancreatitis history unrelated to pancreatic cancer
- Insulin-dependant diabetes mellitus unrelated to pancreatic cancer
- Current or prior coagulopathy disorders unrelated to pancreatic cancer
- ECOG Prognostic Score 3 or 4
- History of grade 3 blood transfusion reaction (life threatening situation)
- Presence of rare and dangerous anti-erythrocyte antibodies preventing from getting a
compatible packed Red Blood Cells for the patient
- Patient already included in another clinical trial
- Pregnancy, breast-feeding or absence of secured contraception
- Unwillingness to sign the informed consent form